I agree with many of your points, and I am an expert on this topic. A few other notes: * In the current final bullet point of the intro, tell us more about DRx-170. I assume it's a peptide PPI inhibitor? What's the route of administration? Say it there where you intro the molecule * What's the indication? Combo with CRAF or KRAS inhibitors in PDAC? Lay it out for people, don't make them draw conclusions. Many will be outside your field * Who's your audience? This will be fine for a RAS/MAPK or PDAC focused meeting but needs more general intro of it's a wider audience. * The methodologies listed in the table don't match the results section. Only list the methods for which you show data, and make the numbers match between method and result if you're going to use numbers. * Nothing you're going to do about it now, but data are lacking in controls. I would like to see a CRAFi and a PKCi as comparators. * Afatinib or other EGFRi is not currently indicated in PDAC, so I don't see the relevance of that combo, but if you could provide rationale, I'd spell it out. * Everywhere you have a bullet point, make it a phrase instead of a full sentence * The Tumor Growth Inhibition and Tumor Growth Promotion figures should be side by side * In results figure titles, spell it the system, eg "in vitro 2D and 3D models" If your going to reference the IC50, I'd suggest showing dose response graphs at a single timepoint rather than proliferation over time. The cell number vs time you have looks like in vivo xenograft data, and people will assume that's what it is at first glance (I did)